Glaxo gets global rights to MorphoSys’ rheumatoid arthritis antibody MOR103
MorphoSys AG (fully human antibody technologies) has granted GlaxoSmithKline PLC worldwide rights to its lead candidate MOR103, in Phase I/II for mild-to-moderate rheumatoid arthritis, and in Phase I for multiple sclerosis. MOR103 was renamed otilimab (GSK3196165).
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com